Търсене на изпитвания

AI · Cancer

Намерени 1,993 изпитвания за "Cancer" Стр. 98 от 100

Активно (без набиране) Фаза 3

A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study

Cancer

This is an open-label, multicenter, extension study. Patients who are receiving clinical benefit from atezolizumab monotherapy or atezolizumab in combination with other agent(s) or combination/comparator agent(s) during participation in a Genentech or Roche-sponsored study (the parent study), who are eligible to continue treatment and who do not have access to the study treatment locally, may continue to receive study treatment in this extension study following roll-over from the parent study.

Начало: 28.02.2019 Край: 05.07.2028 Възраст: от 18 г. Лечение

Australia, Belgium, Brazil +21 Hoffmann-La Roche NCT03768063

Активно (без набиране) Фаза 1

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors

Advanced Solid Tumors Cancer

The study will determine the recommended Phase 2 dose (RP2D) of livmoniplimab (ABBV-151) administered as monotherapy and in combination with budigalimab (ABBV-181) as well as to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of livmoniplimab alone and in combination with budigalimab. The study will consist of 2 parts: dose escalation and dose expansion.

Начало: 21.02.2019 Край: 01.06.2027 Възраст: от 18 г. Лечение

Australia, Belgium, Canada +11 AbbVie NCT03821935

Активно (без набиране) Фаза 2

Testing AZD1775 in Advanced Solid Tumors That Have a Mutation Called SETD2

Clear Cell Renal Cell Carcinoma Locally Advanced Clear Cell Renal Cell Carcinoma Locally Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm +3

This phase II trial studies how well adavosertib works in treating patients with SETD2-deficient solid tumors that have spread to other places in the body (advanced/metastatic). Adavosertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Начало: 29.01.2019 Край: 22.04.2027 Възраст: от 18 г.

United States National Cancer Institute (NCI) NCT03284385

Активно (без набиране) Фаза 3

Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC

Triple Negative Breast Cancer

The GLORIA study is a Phase III, randomized, open-label study to prospectively evaluate the efficacy and safety of adagloxad simolenin (OBI 822)/OBI-821 in the adjuvant treatment of patients with high risk, early stage Globo-H Positive TNBC.

Начало: 05.12.2018 Край: 30.12.2027 Възраст: от 18 г. Лечение

Australia, Brazil, China +10 OBI Pharma, Inc NCT03562637

Активно (без набиране)

Optimal Prostate Study

Prostate Cancer

To compare the toxicity, rate of local control, biochemical failure rate and quality of life of three different radiotherapy techniques (moderate hypofractionation, stereotactic body radiotherapy (SBRT) and standard radiotherapy plus 2 fractions of SBRT (BOOSTER)

Начало: 02.10.2018 Край: 01.08.2028 Възраст: от 18 г. Лечение

Australia Royal North Shore Hospital NCT03386045

Активно (без набиране) Фаза 2

Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors

Colorectal Neoplasms Carcinoma, Non-Small-Cell Lung Exocrine Pancreatic Cancer Carcinoma, Squamous Cell of Head and Neck

This trial will study tisotumab vedotin to find out whether it is an effective treatment alone or with other anticancer drugs for certain solid tumors and what side effects (unwanted effects) may occur. There are seven parts to this study. * In Part A, participants will receive tisotumab vedotin every 3 weeks (3-week cycles). * In Part B, participants will receive tisotumab vedotin on Days 1, 8, and 15 every 4-week cycle. * In Part C, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part D, participants will be given treatment on Day 1 of every 3-week cycle. * Participants in Part D will get tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin * In Part E, participants will receive tisotumab vedotin on Days 1 and 15 of every 4-week cycle. * In Part F, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part F will get tisotumab vedotin with pembrolizumab. * In Part G, participants will receive tisotumab vedotin on Days 1, 15, and 29 of every 6-week cycle. Participants in Part G will get tisotumab vedotin with pembrolizumab and carboplatin. The objectives of the study have been achieved. Therefore, the study will transition to a long-term extension phase (LTEP). * In LTEP, participants still receiving clinical benefit based on the investigator's assessment and remaining on treatment may continue receiving treatment. * Participants will still receive tisotumab vedotin with either: * Pembrolizumab or, * Pembrolizumab and carboplatin, or * Pembrolizumab and cisplatin

Начало: 25.06.2018 Край: 31.03.2027 Възраст: от 18 г.

Canada, France, Germany +4 Seagen, a wholly owned subsidiary of Pfizer NCT03485209

Активно (без набиране) Фаза 3

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Hepatocellular Carcinoma Liver Cancer

This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence

Начало: 18.04.2018 Край: 27.02.2031 Възраст: от 18 г. Лечение

Argentina, Australia, Belgium +21 Bristol-Myers Squibb NCT03383458

Активно (без набиране) Фаза 1

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

Lung Neoplasms Carcinoma, Non-Small-Cell Lung Carcinoma, Small Cell Malignant Mesothelioma, Advanced +9

CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.

Начало: 20.09.2017 Край: 01.12.2025 Възраст: от 18 г. Лечение

Australia, France, New Zealand +6 Checkpoint Therapeutics, Inc. NCT03212404

Активно (без набиране) Фаза 3

A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)

Cancer

This is an open-label, multicenter, non-randomized extension and long-term observational study. Participants receiving atezolizumab monotherapy or atezolizumab combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study) and who continue to receive study treatment at the time of the parent-study closure and do not have access to the study treatment locally are eligible for continued treatment in the extension study. Dosing regimen for a given participant and indication will be the same or equivalent to the respective parent study protocol. Study treatment in the extension study can continue until disease progression or beyond if the patient continues to derive clinical benefit as judged by the investigator and if allowed by the parent study or local prescribing information until death; withdrawal of study consent; unacceptable toxicity; pregnancy; patient non-compliance; or study termination by the Sponsor, whichever occurs first.

Начало: 20.09.2017 Край: 06.03.2030 Лечение

Argentina, Australia, Belgium +27 Hoffmann-La Roche NCT03148418

Активно (без набиране)

Ovarian Tissue Cryopreservation in Children

Cancer

The Institutional Review Board (IRB) protocol is being designed to offer ovarian tissue cryopreservation to female pediatric patients (birth-17 years of age) with fertility threatening medical diagnoses or facing surgery, chemotherapy or radiation therapy that may cause loss of reproductive potential. Because this procedure is currently considered experimental, the establishment of an IRB protocol under which this opportunity can be offered is needed.

Начало: 16.03.2017 Край: 22.01.2040 Възраст: до 17 г.

United States Mayo Clinic NCT02646384

Активно (без набиране) Фаза 1

A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors

Advanced Solid Tumors Cancer

This is a dose-escalation study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of ABBV-927, and to determine the maximum tolerated dose (MTD) or recommended Phase 2 dose (RPTD) for ABBV-927 when administered as monotherapy or as combination therapy with ABBV-181 in participants with advanced solid tumors.

Начало: 22.02.2017 Край: 01.09.2026 Възраст: от 18 г. Лечение

Australia, Canada, France +4 AbbVie NCT02988960

Активно (без набиране)

Assessing How Normal Variations in CT Scanning Affects Its Interpretation

Colorectal Cancer Metastatic

The purpose of the study is to see how measurements of tumor differences vary with slight changes in CT scan parameters. Reproducible radiomic features can be extracted for abdominal tumors, and specifically colorectal liver metastases, imaged with clinical CT scanners even in the setting of variable scan parameters and variable contrast timing. Participants will be consented to undergo an additional CT of their abdomen.

Начало: 27.01.2017 Край: 27.01.2027 Възраст: от 18 г.

United States Memorial Sloan Kettering Cancer Center NCT03038568

Активно (без набиране)

A Longitudinal Observational Study of the Natural History and Management of Patients With HCC

Hepatocellular Cancer

TARGET-HCC is a longitudinal, observational study of patients being managed for HCC in usual clinical practice. TARGET-HCC will create a research registry of participants with HCC within academic and community real-world practices in order to assess the safety and effectiveness of the entire spectrum of current and future therapies across diverse populations.

Начало: 01.12.2016 Край: 01.02.2027 Възраст: от 18 г.

France, Germany, Italy +2 Target PharmaSolutions, Inc. NCT02954094

Активно (без набиране)

Liver Function Investigation With SPECT

Liver Cancer, Adult

This is a Phase 1 pilot study to assess feasibility and utility of 99mTc-mebrofenin hepatobiliary scintigraphy for measurement of functional liver change due to radiotherapy.

Начало: 19.10.2016 Край: 31.12.2026 Възраст: 18–100 г.

Australia Royal North Shore Hospital NCT02967848

Активно (без набиране) Фаза 1/2

A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.

Ovarian Breast SCLC Gastric Cancers

The purpose of this study is to look at the effectiveness, safety, and antitumor activity of study drugs MEDI4736 in combination with olaparib (modules 1, 2, 3, 4, 5 and 7) and MEDI4736 in combination with olaparib and bevacizumab (module 6). It will also examine what happens to the study drugs in the body and investigate how well the combination between MEDI4736, olaparib and bevacizumab is tolerated.

Начало: 17.03.2016 Край: 17.09.2026 Възраст: 18–130 г.

France, Israel, Netherlands +4 AstraZeneca NCT02734004

Активно (без набиране) Фаза 3

A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC

Prostate Cancer

The purpose of this study is to determine if the addition of apalutamide to ADT provides superior efficacy in improving radiographic progression-free survival (rPFS) or overall survival (OS) for participants with mHSPC.

Начало: 27.11.2015 Край: 31.12.2027 Възраст: от 18 г. Лечение

Argentina, Australia, Brazil +19 Aragon Pharmaceuticals, Inc. NCT02489318

Активно (без набиране) Фаза 2

Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Breast Cancer Cholangiocarcinoma Colorectal Cancer Head and Neck Neoplasms +12

This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

Начало: 19.11.2015 Край: 14.05.2026 Възраст: от 18 г. Лечение

Australia, Belgium, China +13 Hoffmann-La Roche NCT02568267

Активно (без набиране) Фаза 3

Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)

Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer

The main objectives of the PATHOS study are: To assess whether swallowing function can be improved following transoral resection of HPV-positive OPSCC, by reducing the intensity of adjuvant treatment protocols. The aim is to personalise treatment, based on disease biology (HPV status and pathology findings), to optimise patient outcomes. To demonstrate the non-inferiority of reducing the intensity of adjuvant treatment protocols in terms of overall survival in the reduced intensity treatment arms.

Начало: 01.10.2015 Край: 01.04.2028 Възраст: от 18 г. Лечение

Australia, France, Germany +2 Lisette Nixon NCT02215265

Активно (без набиране)

PET Avidity in Cachexia-Inducing Lung and Gastrointestinal Tumors

Cachexia; Cancer

PET has an established role in the initial staging of patients with newly diagnosed lung and gastrointestinal tumors.PET avidity is described with both maximum and mean standardized uptake values.Malignant cells have increased activity on PET, defined as the standardized uptake value (SUV), with increased uptake of FDG in tumor due to elevated levels of GLUT receptors, elevated intracellular levels of hexokinase and increased rates of glycolysis. However, there is a subset of patients with lung and gastrointestinal tumors that are not PET avid.These patients may present with clinically and systemically aggressive disease with a declining performance status and/or weight loss.

Начало: 26.11.2013 Край: 31.12.2027 Възраст: 18–99 г.

United States University of Texas Southwestern Medical Center NCT03568019

Активно (без набиране) Фаза 3

Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC

Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb - IV

The purpose of this study is to assess the efficacy of selumetinib in combination with docetaxel (75mg/m2) vs placebo in combination with docetaxel (75mg/m2) in patients with locally advance or metastatic NSCLCs that harbor mutations of KRAS. This study will also assess the PK, safety, patient reported outcomes (PRO) and tolerability profile of the selumetinib/docetaxel combination, compared to placebo in combination with docetaxel

Начало: 25.09.2013 Край: 31.12.2025 Възраст: 18–130 г. Лечение

Argentina, Australia, Belgium +21 AstraZeneca NCT01933932

1 … 96 97 98 99 100